期刊
JOURNAL OF THE AMERICAN DENTAL ASSOCIATION
卷 142, 期 11, 页码 1243-1251出版社
AMER DENTAL ASSOC
DOI: 10.14219/jada.archive.2011.0108
关键词
Oral and maxillofacial pathology; alveolar bone; antiresorptive agent-induced ostenecrosis of the jaw; bisphosphonate-associated osteonecrosis; jaw; oral and mandibular diseases; oral pathology
资金
- Eli Lilly
- Novartis
- Amgen
- Merck Co.
- Genentech
Background. This narrative review of osteonecrosis of the jaw in patients with low bone mass receiving treatment with antiresorptive agents is based on an appraisal of the literature by an advisory committee of the American Dental Association Council on Scientific Affairs. It updates the committee's 2008 advisory statement. Methods. The authors searched MEDLINE for literature published between May 2008 (the end date of the last search) and February 2011. Results. This report contains recommendations based on the findings of the literature search and on expert opinion that relate to general dentistry; periodontal disease management; implant placement and maintenance; oral and maxillofacial surgery; endodontics; restorative dentistry and prosthodontics; orthodontics; and C-terminal telopeptide testing and drug holidays. Conclusions. The highest reliable estimate of antiresorptive agent-induced osteonecrosis of the jaw (ARONJ) prevalence is approximately 0.10 percent. Osteoporosis is responsible for considerable morbidity and mortality. Therefore, the benefit provided by antiresorptive therapy outweighs the low risk of developing osteonecrosis of the jaw. Clinical Implications. An oral health program consisting of sound hygiene practices and regular dental care may be the optimal approach for lowering ARONJ risk. No validated diagnostic technique exists to determine which patients are at increased risk of developing ARONJ. Discontinuing bisphosphonate therapy may not lower the risk but may have a negative effect on low-bone-mass treatment outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据